arrow_back Back to App

Affordable COVID-19 Drugs: Ending Monopolies and Price Gouging.

This act aims to ensure that COVID-19 drugs developed with government support are affordable and accessible to everyone. It means companies cannot create monopolies or artificially inflate prices, protecting citizens from excessive treatment costs and ensuring broad access to essential therapies.
Key points
COVID-19 drugs developed with federal support must be affordable and accessible to all.
Pharmaceutical companies cannot create monopolies or price gouge for COVID-19 drugs if they received federal support.
The government can grant licenses for drug production if original manufacturers refuse to ensure broad access.
Companies must report their expenditures on research, development, and marketing of COVID-19 drugs, including federal support received.
In cases of excessive drug pricing during a public health emergency, the government can revoke market exclusivity and allow other companies to produce.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_597
Sponsor: Rep. Schakowsky, Janice D. [D-IL-9]
Process start date: 2021-01-28
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Pandemic Treatment Access and Affordability Act of 2021

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_597.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2021-01-28.

What are the main provisions?

Key points include:

  • COVID-19 drugs developed with federal support must be affordable and accessible to all.
  • Pharmaceutical companies cannot create monopolies or price gouge for COVID-19 drugs if they received federal support.
  • The government can grant licenses for drug production if original manufacturers refuse to ensure broad access.
  • Companies must report their expenditures on research, development, and marketing of COVID-19 drugs, including federal support received.
  • In cases of excessive drug pricing during a public health emergency, the government can revoke market exclusivity and allow other companies to produce.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Schakowsky, Janice D. [D-IL-9].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Economy